First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results
Permalink : https://ousar.lib.okayama-u.ac.jp/71192
| FullText URL | |
| Author |
Takahashi, Yuko
Department of Breast and Endocrine Surgery, Okayama University Hospital
Nakamoto, Shogo
Department of Breast and Endocrine Surgery, Okayama University Hospital
Tanioka, Maki
Department of Breast and Endocrine Surgery, Okayama University Hospital
Shien, Tadahiko
Department of Breast and Endocrine Surgery, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
| Keywords | Selective estrogen receptor degrader (SERD)
aromatase inhibitor (AI)
endocrine therapy (ET)
hormone receptor-positive (HR+)
advanced breast cancer
|
| Published Date | 2026-04
|
| Publication Title |
Chinese Clinical Oncology
|
| Volume | volume15
|
| Issue | issue2
|
| Publisher | AME Publishing Company
|
| Start Page | 22
|
| ISSN | 2304-3865
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © AME Publishing Company.
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.21037/cco-2025-1-175
|
| License | https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| Citation | Takahashi Y, Nakamoto S, Tanioka M, Shien T. First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results. Chin Clin Oncol 2026;15(2):22. doi: 10.21037/cco-2025-1-175
|
